Skip to main content

Advertisement

SpringerLink
Log in

Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis

Results from a 1-Year, Multicentre, Open-Label, Single-Arm Study in a Clinical Setting

  • Original Research Article
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

Abstract

Background: Data investigating the effect of etanercept on work productivity and healthcare resource utilization in Canadian patients in a clinical setting is limited.

Objective: The aim of the study was to describe work productivity and healthcare resource utilization in patients with psoriasis prescribed etanercept.

Methods: A 12-month, phase IV, non-randomized, multicentre, open-label, single-arm prospective trial of patients with moderate-to-severe plaque psoriasis was conducted between March 2006 and July 2009 in 37 community dermatology practice sites across Canada.

A total of 246 patients were enrolled. Major eligibility criteria: ≥18 years of age; diagnosis of moderate-to-severe plaque psoriasis at baseline (Physician Global Assessment [PGA] ≥3, scale 0–5); able to start etanercept therapy as per product monograph.

Patients received etanercept (Enbrel®) 50 mg subcutaneously twice weekly for 3 months, then 50 mg once weekly for 9 months.

Outcomes were measured by average change and average percent change from baseline at months 3, 6, 9 and 12 on the Work Productivity and Activity Im-pairment (WPAI) and Healthcare Resource Utilization (HRU) questionnaires.

Results: The mean degree of impairment while working ± standard deviation (SD) in the total population decreased from 22.7% ±23.2 at baseline to 6.6% ±14 after 3 months of treatment (p < 0.0001). From baseline to 3 months, overall work impairment± SD decreased from 23.7%±23.7 to 8.3%±16.5 (p < 0.0001) and mean activity impairment outside the workplace decreased from 31.4%±26.4 to 12.9%±22.4 (p<0.0001). All these improvements were sustained to month 12.

Other variables that decreased on average from baseline to month 3, sustained to month 12, included physician office visits (2.3/month±3.5 at baseline to 0.6/month± 1.0 at month 3; p<0.0002), hours of assistance required of family and friends to assist with psoriasis (1.1 hours/week ±2.6 at baseline to 0.3 hours/week ± 1.5 at month 3; p = 0.0002) and amount of time spent on activities to manage psoriasis (5.5 hours/week±6.2 at baseline to 1.9 hours/week±3.7 at month 3; p<0.0001). Also, the amount of out-of-pocket expenses to manage psoriasis decreased from $Can94.9/month±331.6 at baseline to $Can35.7±69.1 at month 12 (p = 0.0153).

Conclusions: Use of etanercept in Canadian patients in a clinical practice setting correlated with improvement in work productivity and reduced HRU after 3 months of treatment, and improvement was sustained up to 12 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May; 58(5): 826–50

    Article  PubMed  Google Scholar 

  2. Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009 Jul; 13(4): 192–7

    PubMed  Google Scholar 

  3. Lachaine J, Martel M, Langley R, et al. Health care resource utilization by patients with psoriasis [abstract no. P3303]. J Am Acad Dermatol 2009; 60 (3 Suppl.1): AB162

    Google Scholar 

  4. Enbrel® (etanercept): product monograph. Mississauga, ON: Amgen Canada, 2010 Jun 11

  5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 Nov; 349(21): 2014–22

    Article  PubMed  CAS  Google Scholar 

  6. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 Jun; 152(6): 1304–12

    Article  PubMed  CAS  Google Scholar 

  7. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 Apr; 56(4): 598–603

    Article  PubMed  Google Scholar 

  8. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008 May; 11(3): 400–7

    Article  PubMed  Google Scholar 

  9. Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010 Aug; 9(8): 928–37

    PubMed  Google Scholar 

  10. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66(2): e33–45

    Article  PubMed  CAS  Google Scholar 

  11. Driessen RJ, Bisschops LA, Adang EM, et al. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010 Jun; 162(6): 1324–9

    Article  PubMed  CAS  Google Scholar 

  12. Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010 Oct; 163(4): 807–16

    Article  PubMed  CAS  Google Scholar 

  13. Vender R, Lynde C, Gillbert M, et al. One-year, multicentre, open-label, single-arm study evaluating real-world safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis. J Cutan Med Surg. In press

  14. Vender R, Lynde C, Gilbert M, et al. Etanercept improves quality-of-life outcomes and treatment satisfaction in patients with moderate-to-severe plaque psoriasis in clinical practice. J Cutan Med Surg. In press

  15. Reilly MC, Zbrozek AS, Dukes EM. The validity and re-producibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 Nov; 4(5): 353–65

    Article  PubMed  CAS  Google Scholar 

  16. Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat 2011; 22(6): 337–47

    Article  PubMed  CAS  Google Scholar 

  17. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006 Jan; 367(9504): 29–35

    Article  PubMed  CAS  Google Scholar 

  18. Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 66(2): e67–76

    Article  PubMed  CAS  Google Scholar 

  19. Zhang W, Bansback N, Guh D, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008 Sep; 35(9): 1729–36

    PubMed  Google Scholar 

  20. Maksymowych WP, Gooch KL, Wong RL, et al. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010 Feb; 37(2): 385–92

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Amgen Canada Inc. and Pfizer Canada Inc.

Amgen Canada Inc. oversaw the design, conduct, and collection of data in the study and assisted in the analysis and interpretation of data.

Dr Vender has received honoraria for his roles as investigator, speaker, and for participating in advisory boards from Abbott, Astellas, Pfizer-Amgen, Merck/Schering, Janssen and Ortho Biotech. Dr Lynde has received honoraria and/or grants for his roles as speaker, consultant, and investigator for Abbott, Pfizer-Amgen, Astellas, Galderma, Graceway, Leo Pharma Inc., Merck-Schering, Sanofi Aventis, Schering Plough, Stiefel, Ortho Biotech. Dr Ho has received honoraria and/or grants for his role as investigator and/or speaker for Merck, Abbott, Janessen, Amgen, Novartis and Pfizer; and for participating in advisory boards for Amgen, Astellas, Merck, Novartis, Pfizer, Abbott, Janessen and Basilea. Dr Chau is an employee of Amgen Canada Inc. and has stock options in Amgen Inc. M. Poulin-Costello is an employee of Amgen Canada Inc. and has stock options in Amgen Inc.

We thank Glen Saunders of G. Saunders Enterprises Inc., Drayton Valley, Alberta, for statistical programming support. We thank Jerry Syrotuik, formerly of Amgen Canada Inc., for his contributions to the CAN-EASE study. We also thank Jessica Benzaquen, MSc, and Cheryl D’Abreo, MSc, from The Synapse Group, Burlington, Ontario, who provided medical writing assistance in the form of drafting and revising as per authors’ directions and in accordance with the standards set out by the International Committee of Medical Journal Editors. Medical writing support was funded by Amgen Canada Inc. and Pfizer Canada.

Drs Lynde, Vender, Ho and Chau contributed to the conception and design of the manuscript. Drs Lynde, Vender, Ho and Poulin-Costello contributed to the acquisition of data and critical revision of the manuscript for important intellectual content. All authors contributed to the analysis and interpretation of data and the drafting of the manuscript. Dr Vender acts as guarantor for the content of this manuscript.

Author information

Authors and Affiliations

  1. Dermatrials Research, 132 Young Street, Hamilton, Ontario, L8N 1V6, Canada

    Ronald Vender

  2. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Ronald Vender

  3. Lynde Centre for Dermatology, Markham, Ontario, Canada

    Charles Lynde

  4. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

    Charles Lynde

  5. Department of Dermatology and Skin Science, The Skin Care Centre, University of British Columbia, Vancouver, British Columbia, Canada

    Vincent Ho

  6. Amgen Canada Inc., Mississauga, Ontario, Canada

    Dina Chau & Melanie Poulin-Costello

Authors
  1. Ronald Vender
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Lynde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dina Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melanie Poulin-Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald Vender.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vender, R., Lynde, C., Ho, V. et al. Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis. Appl Health Econ Health Policy 10, 343–353 (2012). https://doi.org/10.1007/BF03261868

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03261868

Keywords

Search

Navigation